Pathophysiology of Preeclampsia and L-Arginine/L-Citrulline Supplementation as a Potential Strategy to Improve Birth Outcomes
- 20 July 2023
- book chapter
- Published by Springer Nature
- Vol. 1428, 127-148
Abstract
In preeclampsia, the shallow invasion of cytotrophoblast cells to uterine spiral arteries, leading to a reduction in placental blood flow, is associated with an imbalance of proangiogenic/antiangiogenic factors to impaired nitric oxide (NO) production. Proangiogenic factors, such as vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), require NO to induce angiogenesis through antioxidant regulation mechanisms. At the same time, there are increases in antiangiogenic factors in preeclampsia, such as soluble fms-like tyrosine kinase type 1 receptor (sFIt1) and toll-like receptor 9 (TLR9), which are mechanism derivates in the reduction of NO bioavailability and oxidative stress in placenta. Different strategies have been proposed to prevent or alleviate the detrimental effects of preeclampsia. However, the only intervention to avoid the severe consequences of the disease is the interruption of pregnancy. In this scenario, different approaches have been analysed to treat preeclamptic pregnant women safely. The supplementation with amino acids is one of them, especially those associated with NO synthesis. In this review, we discuss emerging concepts in the pathogenesis of preeclampsia to highlight L-arginine and L-citrulline supplementation as potential strategies to improve birth outcomes. Clinical and experimental data concerning L-arginine and L-citrulline supplementation have shown benefits in improving NO availability in the placenta and uterine-placental circulation, prolonging pregnancy in patients with gestational hypertension and decreasing maternal blood pressure. Keywords Preeclampsia Endothelial dysfunction Nitric oxide L-Arginine L-CitrullineKeywords
This publication has 160 references indexed in Scilit:
- Preeclampsia 2012Journal of Pregnancy, 2012
- Nitric oxide generation affects pro- and anti-angiogenic growth factor expression in primary human trophoblastPlacenta, 2011
- Intracellular l-arginine concentration does not determine NO production in endothelial cells: Implications on the “l-arginine paradox”Biochemical and Biophysical Research Communications, 2011
- Role of Reactive Oxygen Species During Hypertension in Response to Chronic Antiangiogenic Factor (sFlt-1) Excess in Pregnant RatsAmerican Journal of Hypertension, 2011
- Reduced l-Arginine Transport and Nitric Oxide Synthesis in Human Umbilical Vein Endothelial Cells from Intrauterine Growth Restriction Pregnancies is Not Further Altered by HypoxiaPlacenta, 2009
- The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational ageThe Journal of Maternal-Fetal & Neonatal Medicine, 2008
- A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonateThe Journal of Maternal-Fetal & Neonatal Medicine, 2008
- Pharmacokinetic and pharmacodynamic properties of oral L‐citrulline and L‐arginine: impact on nitric oxide metabolismBritish Journal of Clinical Pharmacology, 2007
- Pathophysiology of Preeclampsia: Linking Placental Ischemia/Hypoxia with Microvascular DysfunctionMicrocirculation, 2002
- Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia.Journal of Clinical Investigation, 1996